Precision Medicine for Relapsed Multiple Myeloma on the Basis of an Integrative Multiomics Approach

PURPOSE: Multiple myeloma (MM) is a malignancy of plasma cells, with a median survival of 6 years. Despite recent therapeutic advancements, relapse remains mostly inevitable, and the disease is fatal in the majority of patients. A major challenge in the treatment of patients with relapsed MM is the...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JCO Precis Oncol
Main Authors: Laganà, Alessandro, Beno, Itai, Melnekoff, David, Leshchenko, Violetta, Madduri, Deepu, Ramdas, Dennis, Sanchez, Larysa, Niglio, Scot, Perumal, Deepak, Kidd, Brian A., Miotto, Riccardo, Houldsworth, Jane, Shaknovich, Rita, Chari, Ajai, Cho, Hearn Jay, Barlogie, Bart, Jagannath, Sundar, Dudley, Joel T., Parekh, Samir
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2018
Assuntos:
Original Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6350920/
https://ncbi.nlm.nih.gov/pubmed/30706044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.18.00019
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados